Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus.
The 2L21 epitope of the VP2 protein from the canine parvovirus (CPV), fused to the cholera toxin B subunit (CTB-2L21), was expressed in transgenic tobacco chloroplasts. Mice and rabbits that received protein-enriched leaf extracts by parenteral route produced high titers of anti-2L21 antibodies able to recognize the VP2 protein. Rabbit sera were able to neutralize CPV in an in vitro infection assay with an efficacy similar to the anti-2L21 neutralizing monoclonal antibody 3C9. Anti-2L21 IgG and seric IgA antibodies were elicited when mice were gavaged with a suspension of pulverized tissues from CTB-2L21 transformed plants. Combined immunization (a single parenteral injection followed by oral boosters) shows that oral boosters help to maintain the anti-2L21 IgG response induced after a single injection, whereas parenteral administration of the antigen primes the subsequent oral boosters by promoting the induction of anti-2L21 seric IgA antibodies. Despite the induced humoral response, antibodies elicited by oral delivery did not show neutralizing capacity in the in vitro assay. The high yield of the fusion protein permits the preparation of a high number of vaccine doses from a single plant and makes feasible the oral vaccination using a small amount of crude plant material. However, a big effort has still to be done to enhance the protective efficacy of subunit vaccines by the oral route.
Molina
Andrea
A
Instituto de Agrobiotecnología, Universidad Pública de Navarra-CSIC, Campus Arrosadía, 31006 Pamplona, Spain.
Veramendi
Jon
J
Hervás-Stubbs
Sandra
S
D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology; D002736:Chloroplasts / Q000235:genetics; D002772:Cholera Toxin / Q000276:immunology / Q000378:metabolism; D018985:Epitopes, B-Lymphocyte / Q000235:genetics / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007271:Injections, Intradermal; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D010322:Parvoviridae Infections / Q000097:blood / Q000276:immunology*; D017993:Parvovirus, Canine / Q000737:chemistry / Q000276:immunology*; D010936:Plant Extracts; D030821:Plants, Genetically Modified; D011817:Rabbits; D014026:Nicotiana / Q000235:genetics; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage*
D000914:Antibodies, Viral; D036022:Capsid Proteins; D018985:Epitopes, B-Lymphocyte; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D010936:Plant Extracts; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D002772:Cholera Toxin